ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.
http://www.priceseries.com/trade/ADMA-ADMA-Biologics-Inc-stock-gains-27-percent-a-Trade-Record-by-priceSeries-2018071920180813.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments